Esperion Therapeutics Inc (NASDAQ:ESPR) shares dropped 8.9% on Thursday . The company traded as low as $46.65 and last traded at $47.00, approximately 729,293 shares changed hands during mid-day trading. An increase of 44% from the average daily volume of 507,648 shares. The stock had previously closed at $51.59.
ESPR has been the subject of several research reports. Cowen reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Wednesday, November 6th. Northland Securities reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, August 29th. Stifel Nicolaus dropped their price objective on shares of Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, September 17th. BidaskClub upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 25th. Finally, ValuEngine raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $70.44.
The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -6.63 and a beta of 1.93. The company has a fifty day moving average of $43.51 and a two-hundred day moving average of $42.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.41 and a current ratio of 4.41.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.95) by ($0.42). The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $0.99 million. During the same period in the previous year, the business earned ($1.86) EPS. Equities analysts forecast that Esperion Therapeutics Inc will post -4.03 EPS for the current year.
In other Esperion Therapeutics news, CEO Timothy M. Mayleben purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was bought at an average cost of $36.98 per share, for a total transaction of $184,900.00. Following the completion of the transaction, the chief executive officer now owns 83,663 shares in the company, valued at $3,093,857.74. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Target N. V. Biotech purchased 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was bought at an average price of $37.30 per share, with a total value of $2,797,500.00. Following the completion of the purchase, the insider now owns 3,727,964 shares of the company’s stock, valued at approximately $139,053,057.20. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new stake in shares of Esperion Therapeutics during the 1st quarter valued at $186,000. Steward Partners Investment Advisory LLC acquired a new position in Esperion Therapeutics in the second quarter valued at about $165,000. Virginia Retirement Systems ET AL acquired a new position in Esperion Therapeutics in the second quarter valued at about $219,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Esperion Therapeutics during the second quarter worth about $1,280,000. Finally, Aperio Group LLC bought a new stake in Esperion Therapeutics during the second quarter worth about $29,000. Hedge funds and other institutional investors own 97.77% of the company’s stock.
About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: Stop Order Uses For Individual Investors
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.